Open AccessTocilizumab is recommended for the treatment of severe COVID-19
Author(s) -
Yonggang Zhou,
Haiming Wei
Publication year - 2020
Publication title -
ebiomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.596
H-Index - 63
ISSN - 2352-3964
DOI - 10.1016/j.ebiom.2020.103045
Subject(s) - tocilizumab , medicine , immunology , antibody , proinflammatory cytokine , interleukin 6 , prospective cohort study , coronavirus , virology , covid-19 , cytokine , disease , inflammation , rheumatoid arthritis , infectious disease (medical specialty)
a The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China b Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medicine and Medical Center, University of Science and Technology of China, Hefei, Anhui 230001, China Hefei National Laboratory for Physical Sciences at Microscale, University of Science and Technology of China, Hefei, Anhui 230001, China
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom